Related Experiment Videos
Azathioprine formulation optimizes metabolite profile in inflammatory bowel disease
T Stevens1, J P Achkar, K Easley
1Department of Gastroenterology and Hepatology, Center for Inflammatory Bowel Disease, Cleveland Clinic Foundation, OH 44195, USA. stevent@ccf.org
Alimentary Pharmacology & Therapeutics
|September 9, 2004
Summary
Azathioprine may offer metabolic advantages over mercaptopurine by correlating dose with 6-tioguanine nucleotides and reducing 6-methylmercaptopurine levels. 5-aminosalicylic acid use increases 6-methylmercaptopurine but does not affect 6-tioguanine levels.
Area of Science:
- Pharmacology
- Gastroenterology
- Drug Metabolism
Background:
- Mercaptopurine metabolism is influenced by drug formulation (mercaptopurine vs. azathioprine) and concurrent 5-aminosalicylic acid (5-ASA) use.
- Understanding these influences is crucial for optimizing treatment in inflammatory bowel disease (IBD).
Purpose of the Study:
- To investigate the impact of drug dose, formulation (mercaptopurine vs. azathioprine), and 5-ASA use on mercaptopurine metabolism.
- To analyze metabolite levels, specifically 6-tioguanine nucleotides (6-TGN) and 6-methylmercaptopurine (6-MMP).
Main Methods:
- Analysis of metabolites from 131 IBD patients.
- Logistic regression to correlate drug dose with metabolite levels.
- Multivariate analysis to assess the effects of drug formulation and 5-ASA use.
Main Results:
- Azathioprine formulation showed a positive correlation between dose and 6-TGN levels, unlike mercaptopurine.
- While mean 6-TGN levels were similar between formulations, mean 6-MMP levels were higher with mercaptopurine.
- 5-ASA use did not alter 6-TGN levels but significantly increased 6-MMP levels.
Conclusions:
- Azathioprine may offer metabolic advantages due to dose-dependent 6-TGN levels and lower 6-MMP levels.
- 5-ASA use increases 6-MMP, potentially impacting safety, without significantly affecting therapeutic 6-TGN levels.